139 related articles for article (PubMed ID: 9472084)
1. Presence and characteristics of receptors for [D-Trp6]luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer.
Srkalovic G; Schally AV; Wittliff JL; Day TG; Jenison EL
Int J Oncol; 1998 Mar; 12(3):489-98. PubMed ID: 9472084
[TBL] [Abstract][Full Text] [Related]
2. Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma.
Srkalovic G; Wittliff JL; Schally AV
Cancer Res; 1990 Mar; 50(6):1841-6. PubMed ID: 2155060
[TBL] [Abstract][Full Text] [Related]
3. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma.
Srkalovic G; Szende B; Redding TW; Groot K; Schally AV
Proc Soc Exp Biol Med; 1989 Dec; 192(3):209-18. PubMed ID: 2574866
[TBL] [Abstract][Full Text] [Related]
4. Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia.
Fekete M; Redding TW; Comaru-Schally AM; Pontes JE; Connelly RW; Srkalovic G; Schally AV
Prostate; 1989; 14(3):191-208. PubMed ID: 2471961
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix.
Halmos G; Schally AV; Kahan Z
Int J Oncol; 2000 Aug; 17(2):367-73. PubMed ID: 10891548
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer.
Fekete M; Wittliff JL; Schally AV
J Clin Lab Anal; 1989; 3(3):137-47. PubMed ID: 2569034
[TBL] [Abstract][Full Text] [Related]
7. Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer.
Fekete M; Zalatnai A; Schally AV
Cancer Lett; 1989 May; 45(2):87-91. PubMed ID: 2567204
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone.
Yano T; Pinski J; Radulovic S; Schally AV
Proc Natl Acad Sci U S A; 1994 Mar; 91(5):1701-5. PubMed ID: 8127868
[TBL] [Abstract][Full Text] [Related]
9. Membrane receptors for peptides in experimental and human pancreatic cancers.
Fekete M; Zalatnai A; Comaru-Schally AM; Schally AV
Pancreas; 1989; 4(5):521-8. PubMed ID: 2573055
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor.
Milovanovic SR; Radulovic S; Schally AV
Breast Cancer Res Treat; 1992; 24(2):147-58. PubMed ID: 8443402
[TBL] [Abstract][Full Text] [Related]
11. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice.
Lamharzi N; Halmos G; Jungwirth A; Schally AV
Int J Oncol; 1998 Sep; 13(3):429-35. PubMed ID: 9683774
[TBL] [Abstract][Full Text] [Related]
12. Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin.
Kadar T; Redding TW; Ben-David M; Schally AV
Proc Natl Acad Sci U S A; 1988 Feb; 85(3):890-4. PubMed ID: 2893378
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.
Yano T; Pinski J; Halmos G; Szepeshazi K; Groot K; Schally AV
Proc Natl Acad Sci U S A; 1994 Jul; 91(15):7090-4. PubMed ID: 7518926
[TBL] [Abstract][Full Text] [Related]
14. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines.
Emons G; Ortmann O; Becker M; Irmer G; Springer B; Laun R; Hölzel F; Schulz KD; Schally AV
Cancer Res; 1993 Nov; 53(22):5439-46. PubMed ID: 8221683
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.
Miyazaki M; Nagy A; Schally AV; Lamharzi N; Halmos G; Szepeshazi K; Groot K; Armatis P
J Natl Cancer Inst; 1997 Dec; 89(23):1803-9. PubMed ID: 9392622
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
Pinski J; Reile H; Halmos G; Groot K; Schally AV
Int J Cancer; 1994 Oct; 59(1):51-5. PubMed ID: 7927904
[TBL] [Abstract][Full Text] [Related]
17. Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma.
Milovanovic SR; Monje E; Szepeshazi K; Radulovic S; Schally A
J Cancer Res Clin Oncol; 1993; 119(5):273-8. PubMed ID: 8382705
[TBL] [Abstract][Full Text] [Related]
18. Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells.
Segal-Abramson T; Kitroser H; Levy J; Schally AV; Sharoni Y
Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2336-9. PubMed ID: 1312718
[TBL] [Abstract][Full Text] [Related]
19. Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75.
Srkalovic G; Bokser L; Radulovic S; Korkut E; Schally AV
Endocrinology; 1990 Dec; 127(6):3052-60. PubMed ID: 2174343
[TBL] [Abstract][Full Text] [Related]
20. Expression of mRNA for luteinizing hormone-releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines.
Lamharzi N; Halmos G; Armatis P; Schally AV
Int J Oncol; 1998 Mar; 12(3):671-5. PubMed ID: 9472110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
